Our initial analysis of over 1,000 glioma patients from the TCGA and CGGA databases, corroborated by our own clinical samples, consistently showed that FTO expression is significantly downregulated in high-grade gliomas and is strongly associated with poor overall survival. This evidence concerns the gene FTO and central nervous system cancer.